Роль эмолентов в предотвращении развития аллергических заболеваний на фоне атопического дерматита у детей

Атопический дерматит (АтД) — одно из наиболее распространенных воспалительных заболеваний мультифакторной природы, проявляющихся преимущественно в детском возрасте. Несмотря на значительный процент случаев самостоятельного регресса болезни с возрастом, в ряде наблюдений демонстрируется иной сценарий развития событий, заканчивающийся персистентным течением АтД и/или формированием на его фоне сопутствующих аллергических патологий, что значительно ухудшает качество жизни пациента и приводит к его социальной дезадаптации. Патогенетическая основа такого пути состоит непосредственно в нарушении эпидермального барьера, формировании транскутанной сенсибилизации и развитии аберрантного аллергического (Th2-) иммунного системного ответа. При этом основная роль в предотвращении данного патологического пути отводится новому классу увлажняющих средств, содержащих в своем составе активные действующие компоненты, — «эмолентам плюс», считающимся краеугольным камнем в терапии и профилактике развития АтД и других аллергических заболеваний. В представленном обзоре литературы приводятся современные данные, касающиеся аспектов патогенеза АтД и развития на его фоне аллергических болезней. Также в работе рассматриваются данные о влиянии эмолентов на восстановление эпидермального барьера и возможностях их использования в качестве профилактических средств.

1. McPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016;61(6):649–655. doi: 10.4103/0019-5154.193674.

2. Pyun BY. Natural history and risk factors of atopic dermatitis in children. Allergy Asthma Immunol Res. 2015;7(2):101–105. doi: 10.4168/aair.2015.7.2.101.

3. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99–106. doi: 10.1016/j.anai.2009.10.002.

4. Jianu E, Ulmeanu R. Links between allergic rhinitis and asthma. Romanian Journal of Rhinology. 2013;3(9):39–44.

5. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018; 121(3):340–347. doi: 10.1016/j.anai.2018.07.006.

6. Spergel J. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6):S118–S127. doi: 10.1016/j.jaci.2003.09.033.

7. Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии. Вопросы современной педиатрии. 2016;15(3):279–294. doi: 10.15690/vsp.v15i3.1566.

8. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111):1225–1232.

9. Pols DHJ, Wartna JB, Moed H, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2): 143–150. doi: 10.3109/02813432.2016.1160629.

10. Kijima A, Murota H, Takahashi A, et al. Prevalence and Impact of Past History of Food Allergy in Atopic Dermatitis. Allergol Int. 2013;62(1):105–112. doi:10.2332/allergolint.12-oa-0468.

11. Dhar S, Srinivas SM. Food Allergy in Atopic Dermatitis. Indian J Dermatol. 2016;61(6):645–648. doi: 10.4103/0019-5154.193673.

12. Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol. 2001;108(5):720–725. doi: 10.1067/mai.2001.119151.

13. Celakovska J, Bukac J. Analysis of food allergy in atopic dermatitis patients — association with concomitant allergic diseases. Indian J Dermatol. 2014;59(5):445–450. doi: 10.4103/0019-5154.139867.

14. Pols DHJ, Wartna JB, van Alphen EI, et al. Interrelationships between Atopic Disorders in Children: A Meta-Analysis Based on ISAAC Questionnaires. PloS One. 20152;10(7):e0131869. doi: 10.1371/journal.pone.0131869.

15. Lau S, Nickel R, Niggemann B, et al. The development of child-hood asthma: lessons from the German Multicentre Allergy Study (MAS). Paediatr Respir Rev. 2002;3(3):265–272. doi: 10.1016/s1526-0542(02)00189-6.

16. Kulig M, Bergmann R, Klettke U, et al. Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol. 1999;103(6):1173–1179. doi: 10.1016/s0091-6749(99)70195-8.

17. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84–92. doi: 10.2500/aap.2019.40.4202.

18. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2009; 9(5):437–446. doi: 10.1097/ACI.0b013e32832e7d36.

19. Yang G, Seok JK, Kang HC, et al. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020;21(8):2867. doi: 10.3390/ijms21082867.

20. Elias PM, Steinhoff M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067–1070. doi: 10.1038/jid.2008.88.

21. Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J Clin Invest. 2007;117(12): 3655–3657. doi: 10.1172/JCI34182.

22. Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation. Front Immunol. 2015;6:353. doi: 10.3389/fimmu.2015.00353.

23. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol. 2001;137(8):1079–1081.

24. Мурашкин Н.Н., Иванов Р.А., Савелова А.А. и др. Роль эпидермального барьера в формировании пищевой аллергии у детей с генодерматозами. Педиатрическая фармакология. — 2019. — Т. 16. — № 4. — С. 234–240. doi: 10.15690/pf.v16i4.2053.

25. McAleer MA, Pohler E, Smith FJD, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol. 2015;136(5):1268–1276. doi: 10.1016/j.jaci.2015.05.002.

26. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immu nol. 2007;120(1):150–155. doi: 10.1016/j.jaci.2007.04.031.

27. Kobayashi J, Inai T, Morita K, et al. Reciprocal regulation of permeability through a cultured keratinocyte sheet by IFN-gamma and IL-4. Cytokine. 2004;28(4–5):186–189. doi: 10.1016/j.cyto.2004.08.003.

28. Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factoralpha and interferon-gamma in human epidermis. J Invest Dermatol. 2005;124(4):786–792. doi: 10.1111/j.0022-202X.2005.23651.x.

29. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–417. doi: 10.1016/j.jaci.2005.10.033.

30. Wehner J, Neuber K. Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol. 2001;145(2):302–305. doi: 10.1046/j.1365-2133.2001.04352.x.

31. Turner MJ, Zhou B. A new itch to scratch for TSLP. Trends Immunol. 2014;35(2):49–50. doi: 10.1016/j.it.2013.12.001.

32. Rinaldi G. The Itch-Scratch Cycle: A Review of the Mecha nisms. Dermatol Pract Concept. 2019;9(2):90–97. doi: 10.5826/dpc.0902a03.

33. Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8–13. doi: 10.1016/j.alit.2016.10.005.

34. Feld M, Garcia R, Buddenkotte J, et al. The pruritusand TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500–508.e24. doi: 10.1016/j.jaci.2016.02.020.

35. Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol. 1998;28(3):769–779. doi: 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H.

36. Lowe AJ, Leung DYM, Tang MLK, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151. doi: 10.1016/j.anai.2017.11.023.

37. Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest. 2012;122(2):440–447. doi: 10.1172/JCI57416.

38. Schafer T, Heinrich J, Wjst M, et al. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol. 1999;104(6):1280–1284. doi: 10.1016/s0091-6749(99)70025-4.

39. De Benedetto A, Kubo A, Beck LA. Skin Barrier Disruption: A Requirement for Allergen Sensitization? J Invest Dermatol. 2012; 132(3):949–963. doi: 10.1038/jid.2011.435.

40. Izadi N, Luu M, Ong PY, Tam JS. The Role of Skin Barrier in the Pathogenesis of Food Allergy. Children (Basel). 2015;2(3):382–402. doi: 10.3390/children2030382.

41. Chin S, Vickery BP. Pathogenesis of food allergy in the pediatric patient. Curr Allergy Asthma Rep. 2012;12(6):621–629. doi: 10.1007/s11882-012-0296-x.

42. Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. doi: 10.1016/j.alit.2016.12.002.

43. Zhang Y, Zhou B. Functions of thymic stromal lymphopoietin in immunity and disease. Immunol Res. 2012;52(3):211–223. doi: 10.1007/s12026-012-8264-z.

44. Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol. 2014;10(11):1463–1474. doi: 10.1586/1744666X.2014.967684.

45. Yoo J, Omori M, Gyarmati D, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005;202(4):541–549. doi: 10.1084/jem.20041503.

46. Kjellman NI, Nilsson L. From food allergy and atopic dermatitis to respiratory allergy. Pediatr Allergy Immunol. 1998;9(11 Suppl):13–17.

47. Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010;63(4):587–593. doi: 10.1016/j.jaad.2009.11.011.

48. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad.2014.03.023.

49. Simpson EL. Atopic dermatitis: a review of topical treatment options. Cur Med Res Opin. 2010;26(3):633–640. doi: 10.1185/03007990903512156.

50. van Zuuren EJ, Fedorowicz Z, Christensen R, et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017; 2(2):CD012119. doi: 10.1002/14651858.CD012119.pub2.

51. Mack Correa CM, Nebus J. Management of patients with atopic dermatitis: the role of emollient therapy. Dermatol Res Pract. 2012;2012:836931. doi: 10.1155/2012/836931.

52. Cork MJ, Danby S. Aqueous cream damages the skin barrier. Br J Derma tol. 2011;164(6):1179–1180. doi: 10.1111/j.1365-2133.2011.10390.x.

53. Lowe AJ, Su JC, Allen KJ, et al. A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol. 2017;178(1):e19–e21. doi: 10.1111/bjd.15747.

54. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: 10.1111/jdv.14891.

55. Левина Ю.Г., Алексеева А.А., Эфендиева К.Е., Вишнёва Е.А., Намазова-Баранова Л.С. Коррекция дисбиоза кожи как неотъемлемая составная часть патогенетической терапии атопического дерматита. Педиатрическая фармакология . 2019; 16(2):97–100. doi: 10.15690/pf.v16i2.2006

56. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023):1109–1122. doi: 10.1016/s0140-6736(15)00149-x.

57. Mandeau A, Aries M-F, Bieber T. et al. Rhealba Oat Plantlet Extract: Evidence of Protein-Free Content and Assessment of Regulatory Activity on Immune Inflammatory Mediators. Planta Med. 2011:77(09);900–906. doi: 10.1055/s-0030-1250649.

58. Stalder JF, Tennstedt D, Deleuran M, et al. Fragility of epidermis and its consequence in dermatology. J Eur Acad Dermatol Venereol. 2014;28(Suppl 4):1–18. doi: 10.1111/jdv.12509.

59. Saint Aroman M, Guillot P, Dahan S, et al. Efficacy of a repair cream containing Rhealba oat plantlets extracts, L-ALA-L-GLU dipeptide, and hyaluronic acid in wound-healing following dermatological acts: a meta-analysis of >2,000 patients in eight countries corroborated by a dermatopediatric clinical case. Clin Cosmet Investig Dermatol. 2018;11:579–589. doi: 10.2147/CCID.S177614.

60. Wollenberg A., Folster-Holst R, Saint Aroman M, et al. Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2018;32(Suppl 1):1–15. doi: 10.1111/jdv.14846.

61. Grimalt R, Mengeaud V, Cambazard F. The Steroid-Sparing Effect of an Emollient Therapy in Infants with Atopic Dermatitis: A Randomized Controlled Study. Dermatology. 2006;214(1):61–67. doi: 10.1159/000096915.

62. Patel N, Feldman SR. Adherence in Atopic Dermatitis. In: Management of Atopic Dermatitis. Fortson EA, Feldman SR, Strowd LC, eds. Springer; 2017. pp. 139–159. doi: 10.1007/978-3-319-64804-0_12.